Status:
RECRUITING
The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Hearing-Related Quality of Life
Lead Sponsor:
Turku University Hospital
Conditions:
Cancer
Hearing Loss Ototoxic
Eligibility:
All Genders
18-75 years
Brief Summary
The study will assess the effect of cancer treatments on speech perception in noise, cognition, and hearing-related quality of life by monitoring 200 cancer patients receiving standard care for their ...
Detailed Description
The study will assess the effects of four different types of cancer treatments on speech perception in noise, hearing thresholds, cognition, and hearing-related quality of life over a follow-up period...
Eligibility Criteria
Inclusion
- written informed consent
- native Finnish speaker
- age-normative hearing
- for participants in the treatment arms: diagnosis of a malignancy that will be treated with curative intent with any of the following: 1) Cisplatin as the main chemotherapeutic agent, 2) oxaliplatin as the main chemotherapeutic agent, 3) cisplatin-based chemoradiation therapy in the head and neck region, 4) radiation therapy in the head and neck region
Exclusion
- inability to provide written informed consent
- Current or prior major otological condition that has affected or has had the potential to affect hearing
- Conductive or asymmetric sensorineural HL of any severity
- Severe sensorineural HL
- Prior malignancy treated with chemotherapeutics or radiation therapy
- Prior use of ototoxic medications
- Any significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the trial, or may influence the result of the trial.
- Any condition that, in the opinion of the investigator, would interfere with adherence to the trial requirements.
- For participants in the treatment arms:
- Allergy or hypersensitivity to trial medications or their ingredients
- Pregnancy or breast-feeding, aim of becoming pregnant during the trial.
Key Trial Info
Start Date :
October 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06551857
Start Date
October 2 2024
End Date
December 31 2030
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku University Hospital
Turku, Southwest Finland, Finland, 20521